secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0001372299-25-000004
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen presents clinical data with significant LLVA improvement (p=0.005) at Year 1 in retinal disease study
--------------------------------------------------------------------------------

- Mean change in LLVA from baseline improved in treated eye vs untreated (p=0.005 at Year 1).
- 75% of patients met responder criterion (6/8) at measured timepoints.
- Mean total atrophy area change at Month 12 showed trend favoring treated eye (p=0.055).
- Mean BCVA (ETDRS) change from baseline reported up to Month 12.
- Presentation includes Year 1 and Year 2 data from the clinical trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000137229925000004/0001372299-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000137229925000004/ocgn-20250616.htm
  HTML page:      https://secwatch.observer/filing/0001372299-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer